Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

The Tortured Path to the Cortisone Discovery

Thomas R. Collins  |  February 17, 2019

CHICAGO—The path to the discovery of cortisone—a top-selling, important drug, with dozens of indications—was complicated by failure, false moves, desperation and obsession. The tale, recounted in the Philip Hench, MD, Memorial Lecture: Crossroads of History & Hope: Discovery & First Use of Cortisone for RA at the 2018 ACR/ARHP Annual Meeting in October, is an…

Filed under:Meeting ReportsRheumatoid Arthritis Tagged with:2018 ACR/ARHP Annual MeetingcortisoneResearch Funding

These 3 Tough Cases from the 2018 Thieves Market Underscore Need for Clinical Diligence

Thomas R. Collins  |  February 17, 2019

CHICAGO—In the Thieves Market session at the 2018 ACR/ARHP Annual Meeting, rheumatologists from around the country presented a slate of challenging cases that emphasized the importance of clinical persistence and attention to detail, and the need to consider diagnoses that might not be common or obvious. Three of them are summarized below. (Look for more…

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual MeetingCancercase reportCheckpoint InhibitorscyclosporineImmunoglobinleprosynifedipinepregabalintacrolimus

What to Do with Erosive, Inflammatory Osteoarthritis

Lara C. Pullen, PhD  |  February 17, 2019

CHICAGO—Is erosive, inflammatory osteoarthritis (EOA) a separate condition from osteoarthritis (OA)? Roberta Ramonda, MD, PhD, a rheumatologist at the University of Padova, Italy, spoke at the 2018 ACR/ARHP Annual Meeting on the clinical presentation of EOA and how it differs from OA. EOA is characterized by a frequent aggressive clinical course and occurs most often…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:2018 ACR/ARHP Annual Meetingclondronateetanercepthand osteoarthritistopical NSAIDs

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD  |  February 17, 2019

As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…

Filed under:Biologics/DMARDsResearch RheumRheumatoid ArthritisSpeak Out Rheum Tagged with:OpinionSpeak Out Rheumatology

Cancer-Associated Myositis: A Case Report & Review of the Literature

Cancer-Associated Myositis: A Case Report & Review of the Literature

Osman Bhatty, MD, Rouhin Sen, MD, & Joseph Nahas, MD  |  February 17, 2019

Since it was first reported in 1916, a correlation between inflammatory myopathies and cancer has been noted in several studies. Population studies have confirmed this relationship, and the phrase cancer-associated myopathy has entered the vernacular. Over the past decade, research efforts have shifted toward revealing associations between autoantibodies and clinical phenotypes. One subset of auto-antigens…

Filed under:ConditionsMyositisOther Rheumatic Conditions Tagged with:Cancercarcinoid syndromecase reportdermatomyositis

Moments That the Words Don’t Reach

Philip Seo, MD, MHS  |  February 12, 2019

There are moments that the words don’t reach There is suffering too terrible to name You hold your child as tight as you can And push away the unimaginable                                     —Lin Manuel Miranda A friend of mine was killed a few days ago. By the time you read this column, the scars will have already started…

Filed under:OpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:bereavementgriefsudden bereavementsudden death

Leadership Support for Division Directors

Carina Stanton  |  February 8, 2019

The ACR has elected a small group of division directors from across the country to serve on the Division Directors Special Committee. The goals of this committee: to better understand the needs of academic rheumatology programs and share with these programs new resources from the ACR and other organizations to support the needs of those…

Filed under:Profiles Tagged with:Division Directors Special CommitteeLeslie Crofford

Walking Ability of OA Patients Linked to Cardiovascular Risk

Arthritis Care & Research  |  February 5, 2019

New research explores the association of the ability to walk and the risk of cardiovascular disease in OA patients compared with the general population. During the study, researchers recorded a six-minute walking distance and measured arterial stiffness of participants. The results: Even among younger people, OA patients could not walk as far as those in the general population. Also, arterial stiffness was inversely associated with walking distance, suggesting walking is important to the cardiovascular risk profile of OA patients…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis Care & ResearchCardiovascular diseaseOsteoarthritisphysical activityriskwalking

FDA Update: Priority Review for Non-Opioid Treatment & New Warning for Fluoroquinolones

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2019

The FDA has granted priority review to a non-opioid, postoperative pain treatment, HTX-011…

Filed under:AnalgesicsDrug Updates Tagged with:bupivacaineFDAfluoroquinolonesHTX-011meloxicamsafety warningU.S. Food and Drug Administration (FDA)

OA Patient-Reported Outcomes Positive for Intra-Articular Injection

Carina Stanton  |  January 21, 2019

In a recent Phase 2 clinical trial, patient-perceived pain and function measures improved with SM04690, an injectable, disease-modifying osteoarthritis treatment currently in development…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:intra-articular Wnt-β catenin inhibitorjoint injectionkneeknee osteoarthritisKnee Osteoarthritis (OA)SM04690

  • « Previous Page
  • 1
  • …
  • 98
  • 99
  • 100
  • 101
  • 102
  • …
  • 243
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences